# Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt

> **NCT01635959** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3170 (actual)

## Conditions studied

- Patients With Upper Gastro-intestinal Symptoms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01635959
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 3170 (ACTUAL)
- **Last updated:** 2014-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01635959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01635959, "Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01635959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*